BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of ...
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the 'Company'), a global device, cell, and gene therapy-enabling company offering precise ...
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati ...
Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.